BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023
24 avr. 2023 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
14 mars 2023 16h15 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- OnkosXcel Therapeutics, LLC (“OnkosXcel”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with...
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
09 mars 2023 07h00 HE
|
BioXcel Therapeutics
IGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team Multiple pivotal data readouts for BXCL501...
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
23 févr. 2023 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today
21 févr. 2023 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium
13 févr. 2023 17h00 HE
|
BioXcel Therapeutics
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrated composite response rate of 25% in patients with metastatic SCNC-variant castration-resistant prostate cancer Company plans to initiate randomized...
BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer
08 févr. 2023 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
11 janv. 2023 07h00 HE
|
BioXcel Therapeutics
Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC Full data will be presented at the 2023 ASCO Genitourinary Cancers Symposium in February ...
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
22 déc. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
19 déc. 2022 07h00 HE
|
BioXcel Therapeutics
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia Estimated 100 million annual Alzheimer’s-related agitation...